Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy
Status:
Not yet recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, single-center Phase Ib/II study to exploratorily evaluate
the tolerability, safety, and efficacy of regorafenib and nivolumab plus chemotherapy in
patients with unresectable advanced/recurrent gastric/ gastroesophageal junction/esophageal
adenocarcinoma.